Below are highlights from the September issue of the Board of Pharmacy newsletter. See the newsletter for additional details and more information.   

• HIV Post-Exposure Prophylaxis and Point-of-Care Testing:  Pharmacist prescriptive authority for the prescribing of HIV post-exposure prophylaxis therapy in conjunction with point-of-care testing was approved by the Board during its April 2021 meeting. Pharmacists who wish to obtain this prescriptive authority must go through Board-approved training and adhere to the Board-approved protocol.  
• Regulation Updates 
  • 16.19.4 NMAC – Medical cannabis 
  • 16.19.20 NMAC – Changes to the scheduling status of certain substances 
  • 16.19.30 NMAC – Changes to the compounding of nonsterile pharmaceuticals.  
  • 16.19.31 NMAC – Emergency Provisions adding a section outlining Board authority to authorize extensions for unavailable training or testing during a declared emergency. This includes pharmacist license under reciprocity, technician registration, or pharmacist prescriptive authority. 

• 2021 Law Update Schedule 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

Below are highlights from the June issue of the New Mexico Board of Pharmacy newsletter. See the newsletter for additional details and more information.  

• As some prescribing practitioners are working to implement the electronic prescriptions for controlled substances requirement that was effective April 1, 2021, the Board issued an "Emergency Dispensing Declaration" from April 1, 2021, through June 30, 2021, and it does not intend to take action against a pharmacist who fills a nonelectronic controlled substance prescription not otherwise subject to the exceptions. 

• Effective June 18, 2021, a healthcare provider may provide a prescription for medical aid in dying to a terminally ill adult who is mentally competent after meeting certain requirements pursuant to HB 47, the Elizabeth Whitefield End-of-Life Options Act
• REMINDER: Be Sure to submit Adverse Drug Event reports to the Board within 15 days as required by regulation. 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

The Board of Pharmacy amended regulations under 16.19.26 NMAC to establish standards for pharmacist prescribing of protocol formulary dangerous drugs and address prescribing of dangerous drugs in conjunction with point-of-care testing. The rule also revises the definition of “hormonal contraception drug therapy” to include formulary products delineated in the written contraception protocol, including emergency contraception. In addition, the rule clarifies requirements for reporting vaccine administration. The rule is effective May 31, 2021.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

The Board of Pharmacy issued a proposed rule establishing standards for pharmacist prescribing of protocol formulary dangerous drugs and prescribing of dangerous drugs in conjunction with point-of-care testing. The rule also revises the definition of “hormonal contraception drug therapy” to include formulary products delineated in the written contraception protocol, including emergency contraception, and clarifies reporting of vaccine administration. The Board will hold a virtual hearing during their April 22-23 meeting.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

The 60-day legislative session adjourned on March 20.

For more information, contact NACDS’ Mary Staples at 817-442-1155.

The Office of Superintendent of Insurance issued a notice to health insurers regarding the use of telehealth services during the COVID pandemic, clarifying that the HIPAA penalty waiver relating to the use by providers of certain communications technologies will continue through the calendar year 2021 and that the coverage parity requirements that apply to behavioral health services are not linked to the declaration of the COVID-19 public health emergency.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.